News
The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with ...
Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...
Pharmalittle: We’re watching Europe moving to reject Elevidys, a FDA panel on SSRI risks, and more
European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...
In an import contrast to events in the USA, UK pharma major GSK late Thursday announced the approval of Blenrep (belantamab ...
The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...
Explore more
GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...
However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, ...
The US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for ...
Rocket Pharmaceuticals announced a restructuring that will include layoffs affecting 30% of its employees. The company is ...
The European Union has given regulatory approval to GSK's drug, Blenrep, for treating relapsed or treatment-resistant forms of blood plasma cell cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results